Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.

Erythropoietin is an essential hormone for red blood cell production. Without it, definitive erythropoiesis does not take place. Under hypoxic conditions, the kidney will produce and secrete erythropoietin to increase the production of red blood cells by targeting CFU-E, proerythroblast and basophilic erythroblast subsets in the differentiation. Erythropoietin has its primary effect on red blood cell progenitors and precursors (which are found in the bone marrow in humans) by promoting their survival through protecting these cells from apoptosis, or cell death.

In this report, we definite one unit for 1ml, except Epoetin-alfa type, which one unit means 10000units/ml
The classification of erythropoietin includes epoetin-alfa, epoetin-beta, darbepoetin-alfa and others. The proportion of epoetin-alfa in 2016 is about 58.53%.

The global Erythropoietin market was valued at US$ 8146.7 million in 2019 and is expected to reach US$ 12140 million by the end of 2026, growing at a CAGR of 5.8% during 2021-2026.
This report focuses on Erythropoietin volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Erythropoietin market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Erythropoietin Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others

Segment by Application
Anemia
Kidney Disorders
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Amgen
Johnson & Johnson
Roche
Galenica
Emcure
Kyowa Hakko Kirin
3SBio
Biocon
LG Life Sciences